Renal osteodystrophy affects nearly all children with chronic renal failure, and growth retardation is major clinical consequence; accordingly, recombinant human growth hormone (rhGH) has been used to enhance linear growth in pediatric patients with end-stage renal disease. Little is known, however, about the effects of rhGH therapy in bone formation and parathyroid gland function in children with renal osteodystrophy.
Showing the most recent 10 out of 1085 publications